Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Cristian, Iaciu"'
Autor:
Elena-Monica BOGHICI, Andreea-Ioana PAROSANU, Ion Cristian IACIU, Mihaela OLARU, Cristina-Florina PIRLOG, Cristina ORLOV-SLAVU, Ana-Maria POPA, Cornelia NITIPIR
Publikováno v:
Modern Medicine, Vol 30, Iss 2, Pp 157-160 (2023)
Breast cancer is one of the most common malignancies, with a 10-year survival rate for early non-metastatic stages of over 80%. However, recurrence or relapse may occur decades after completing therapy, and cancer survivors have also a risk of second
Externí odkaz:
https://doaj.org/article/bff78c217fd9459b87c40618a9f63405
Autor:
Andreea Ioana Parosanu, Cristina Florina Pirlog, Cristina Orlov Slavu, Ioana Miruna Stanciu, Horia-Teodor Cotan, Radu Constantin Vrabie, Ana-Maria Popa, Mihaela Olaru, Cristian Iaciu, Lucian Ioan Bratu, Ionut Florian Baicoianu, Oana Moldoveanu, Catalin Baston, Cornelia Nițipir
Publikováno v:
Current Oncology, Vol 30, Iss 2, Pp 2457-2464 (2023)
Background: Metastatic renal cell carcinoma (mRCC) is an aggressive cancer characterised by an increased recurrence rate and an inadequate response to treatment. This study aimed to investigate the importance of the neutrophil-to-lymphocyte ratio (NL
Externí odkaz:
https://doaj.org/article/0895789e72fe44cf8e12d3a27289df91
Autor:
Cristina-Florina Pîrlog, Andreea Ioana Paroșanu, Cristina Orlov Slavu, Mihaela Olaru, Ana Maria Popa, Cristian Iaciu, Irina Niță, Pompilia Moțatu, Cotan Horia, Loredana Sabina Cornelia Manolescu, Cornelia Nițipir
Publikováno v:
Current Oncology, Vol 29, Iss 12, Pp 9428-9436 (2022)
Immune-checkpoint inhibitors (ICIs) are the most effective treatments nowadays. Nivolumab was the second ICI used for treating solid tumors with amazing results. Patients treated with Nivolumab may react differently to this treatment. Some people tol
Externí odkaz:
https://doaj.org/article/af369dd6c61d480da3673f8b2e269ddf
Autor:
Andreea PAROSANU, Ana-Maria POPA, Cristian IACIU, Mihaela OLARU, Cristina ORLOV-SLAVU, Horia COTAN, Miruna STANCIU, Radu VRABIE, Cornelia NITIPIR
Publikováno v:
Modern Medicine, Vol 29, Iss 1, Pp 93-97 (2022)
Paraneoplastic syndromes of the nervous system are rare disorders, strongly linked with lung cancer. This report aims to explore the challenges in the diagnosis and treatment of a patient with early-stage small cell lung cancer and neurological manif
Externí odkaz:
https://doaj.org/article/ec6491a43f004bd9973907a5016d827e
Autor:
Cristina-Florina Pîrlog, Raluca Costache, Andreea Ioana Paroșanu, Cristina Orlov Slavu, Mihaela Olaru, Ana Maria Popa, Cristian Iaciu, Irina Niță, Pompilia Moțatu, Horia Teodor Cotan, Alexandru Vlad Oprița, Daniel Costache, Loredana Sabina Cornelia Manolescu, Cornelia Nițipir
Publikováno v:
Diagnostics, Vol 13, Iss 11, p 1892 (2023)
Background: Lung cancer (LC) is the first and most lethal cancer in the world; identifying new methods to treat it, such as immune checkpoint inhibitors (ICIs), is needed. ICIs treatment is very effective, but it comes bundled with a series of immune
Externí odkaz:
https://doaj.org/article/71eedd2c07834566a6a2ac720251c1ae
Autor:
Ioana-Miruna Stanciu, Cristina Florina Pirlog, Andrei-Wilhelm Anghel, Andreea Ioana Parosanu, Cristina Mihaela Olaru, Cristina Orlov-Slavu, Ion Cristian Iaciu, Ana Maria Popa, Radu Constantin Vrabie, Cornelia Nitipir
Publikováno v:
Medicina, Vol 59, Iss 4, p 696 (2023)
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors and endocrine therapy are the gold standards for systemic therapy for patients with hormone-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer. Followi
Externí odkaz:
https://doaj.org/article/3937aff8b0fd4bc7a9b4c3be4d446f1b
Autor:
Ioana-Miruna Stanciu, Andreea Ioana Parosanu, Cristina Orlov-Slavu, Ion Cristian Iaciu, Ana Maria Popa, Cristina Mihaela Olaru, Cristina Florina Pirlog, Radu Constantin Vrabie, Cornelia Nitipir
Publikováno v:
Diagnostics, Vol 13, Iss 5, p 987 (2023)
The latest and newest discoveries for advanced and metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer are the three cyclin-dependent kinases 4 and 6 inhibitors (CDK4/6i) in associati
Externí odkaz:
https://doaj.org/article/6c9da4fa657d4d3eb1982d2cad5f926e
Autor:
Cornelia NITIPIR, Andreea PAROSANU, Lucian ALECU, Ana Maria POPA, Cristian IACIU, Mihaela OLARU, Adrian TULIN, Iulian SLAVU, Valentin CALU, Cristina ORLOV-SLAVU
Publikováno v:
Modern Medicine, Vol 27, Iss 4, Pp 253-259 (2020)
Introduction: Cancer related- pain causes a negative psychosocial and physical impact on patients’ lives. The purpose of this review was to investigate the current strategies for cancer pain treatment. Material and Methods: We conducted a PubMed se
Externí odkaz:
https://doaj.org/article/d3c5c067d9b94cf187cc7944c8660f94
Autor:
Cornelia NITIPIR, Andreea PAROSANU, Ana-Maria POPA, Cristian IACIU, Anca PANTEA-STOIAN, Valentin CALU, Cristina ORLOV-SLAVU
Publikováno v:
Modern Medicine, Vol 27, Iss 2, Pp 73-78 (2020)
Multigene assays were developed to guide treatment in early-stage breast cancer and to evaluate the benefit of adjuvant chemotherapy. Patients with invasive breast carcinoma, either T1 or T2, N0 or N1 (one to three positive lymph nodes), with no inv
Externí odkaz:
https://doaj.org/article/46430307f6ea41f7b64e57929285b036
Autor:
Andreea Parosanu, Miruna Stanciu, Cristina Parlog, Cristina Orlov, Mihaela Olaru, Ana Maria Popa, Horia Cotan, Radu Vrabie, Cristian Iaciu, Oana Moldoveanu, Catalin Baston, Cornelia Nitipir
Publikováno v:
International Journal of Innovative Research in Medical Science. 7:743-745
Background: The incidence of metastatic renal cell carcinoma has steadily increased. Therefore, it is essential to identify precise biomarkers to predict survival and improve clinical care. Objectives: This study aimed to evaluate potential prognosti